Tilray Posts Record Revenue, but Cannabis Weakness and a Miss Sink the Stock
Record Q1 revenue of $257.1M rose 23% but missed consensus. Cannabis weakness and no guidance raise weighed on the stock.
/ 8 items
#TLRY↓
DEA Judge Pauses Broader Marijuana Rescheduling — Cannabis Stocks Slide
A DEA judge paused the broader marijuana Schedule III hearing after a GAO report found gaps in federal drug reviews. Medical cannabis already moved in April.
Cannabis Stocks Drop After Early Surge on Limited US Marijuana Rescheduling Move
Cannabis stocks fell after hype faded: US reform helps medical marijuana only, not full market, so investors took profits.
Trump Administration Set to Reclassify Marijuana This Week
The Trump administration is expected to reclassify marijuana from Schedule I to Schedule III as soon as this week, easing research barriers after months of delay.
BrewDog Sold to Cannabis Giant Tilray in £33m Deal
Craft beer icon BrewDog is being acquired by US cannabis and drinks firm Tilray Brands for around £33 million amid financial struggles. Key assets change hands as the Scottish brewer faces big changes.
Tilray Brands Reports Narrower Q2 Loss Despite Mixed Sales Performance
Tilray (TLRY) narrows Q2 losses to $43.5M with 3% revenue growth driven by cannabis gains, though beverage sales decline 21% amid international expansion strategy.